415-P: Prevalence of Gastroparesis Symptoms in Diabetic Patients in the Western Region of Saudi Arabia, 2019

Abstract

Gastroparesis is a well-established diabetes complication with conflicting data regarding its prevalence. Gastroparesis impacts quality of life, increases direct health-care costs and is associated with morbidity and mortality. Other possible consequences include erratic glycemic control, alteration in drug absorption and hypoglycemia. Objectives: To estimate the prevalence of diabetic gastroparesis symptoms in T2DM patients attending PHC centers and to determine the associated factors Methods: A cross sectional study which included a representative sample of patients attending PHC centers of the Ministry of National Guards Health Affairs, Western Region-Saudi Arabia. Simple random sampling technique was adopted to select the study population. Patient interviewing technique was adopted to fill the Arabic version of GSCI. Information on demographics and personal characteristics, diabetes duration, type of treatment and other variables were obtained. Results: The study involved 365 participants, 66.3% were females, 52.9% aged 40-59 years and 31.8% with disease duration 10-20 years. A GCSI with a score of ≥ 1.9 was used to diagnose gastroparesis symptoms. Prevalence of gastroparesis symptoms was 7.9%. The most frequent symptoms were bloating (34.8%) then stomach fullness (26.6%) and the least frequent was vomiting (4.1%). The most frequently used agent was metformin (84.9%). 47.1% of participants had HbA1C between (7-9%) and 37.9% of them have gastroparesis symptoms (p 0.318). 69% of participants with gastroparesis symptoms were using metformin (p 0.012). 10.3% of participants with gastroparesis symptoms were not using any diabetes medications (p 0.037). 25% of participants with CHD had gastroparesis symptoms (p 0.001). Conclusion: Up to our knowledge, this is the 1st local multi-city and primary care-based study. The prevalence of gastroparesis symptoms was 7.9%. Gastroparesis symptoms were significantly associated with the use of metformin, CHD and participants not on any medication. Disclosure A. A. Bukhari: None. M. M. Alsayari: None.